Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 18;13(16):4869.
doi: 10.3390/jcm13164869.

Drug-Related Glomerular Phenotypes: A Global Pharmacovigilance Perspective

Alexandre Baptista  1   2 , Ana M Macedo  1   2 , Ana Marreiros  1   2 , André Coelho  3 , Mark A Perazella  4
Affiliations

Drug-Related Glomerular Phenotypes: A Global Pharmacovigilance Perspective

Alexandre Baptista et al. J Clin Med. .

Abstract

Introduction: Adverse drug reactions are a significant problem in modern society, stemming from the increase in prescribed medications, over-the-counter drugs, and overall polypharmacy. Glomerular disorders are one of the frequently reported renal conditions associated with medication use. VigiBase is a significant tool for evaluating events associated with drug use, and, to the authors' knowledge, no study has yet assessed this database to identify the primary medications associated with glomerular disorders. Materials and Methods: We collected data from VigiBase for 54 years and evaluated data based on global frequencies, disproportionality (IC025 values), nephrotoxic potential, and physiopathological mechanisms. Results: Over the evaluation period, 33.932.051 spontaneous notifications of adverse drug reactions reported in VigiBase were assessed, from which 106.775 notifications of drug-associated glomerular disorders were extracted. The isolated medications were classified as 'potential nephrotoxins' (47.0%), with 40% of the medications lacking scientific references to report any association with the development of glomerular disorders. Among the evaluated medications, Inotersen (IC025 of 8.3), Penicillamine (IC025 6.8), Bevacizumab (IC025 5.9) and Lenvatinib (IC025 5.4) were identified as having the strongest association with these glomerular disorders. For medications classified as 'non-nephrotoxic', a high disproportionality index was observed, suggesting drugs that might be considered as new potential nephrotoxins. Conclusions: Drug-induced glomerular disorders were significantly associated with medications that had no established nephrotoxic role but demonstrated a high disproportionality index in VigiBase. These newly alleged nephrotoxic drugs warrant further evaluation in dedicated studies to assess their true nephrotoxic potential.

Keywords: drug therapy; drug-related side effects and adverse reactions; glomerular diseases; pharmacology; pharmacovigilance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Schroll J.B., Maund E., Gøtzsche P.C. Challenges in coding adverse events in clinical trials: A systematic review. PLoS ONE. 2012;7:e41174. doi: 10.1371/journal.pone.0041174. - DOI - PMC - PubMed
    1. Mehta R.L., Awdishu L., Davenport A., Murray P.T., Macedo E., Cerda J., Chakaravarthi R., Holden A.L., Goldstein S.L. Phenotype standardization for drug-induced kidney disease. Kidney Int. 2015;88:226–234. doi: 10.1038/ki.2015.115. - DOI - PMC - PubMed
    1. Garnier A.-S., Laubacher H., Briet M. Drug-induced glomerular diseases. Therapies. 2023;79:271–281. doi: 10.1016/j.therap.2023.10.010. - DOI - PubMed
    1. Radhakrishnan J., Perazella M.A. Drug-Induced Glomerular Disease. Clin. J. Am. Soc. Nephrol. 2015;10:1287–1290. doi: 10.2215/CJN.01010115. - DOI - PMC - PubMed
    1. Markowitz G.S., Bomback A.S., Perazella M.A. Drug-induced glomerular disease: Direct cellular injury. Clin. J. Am. Soc. Nephrol. 2015;10:1291–1299. doi: 10.2215/CJN.00860115. - DOI - PMC - PubMed

LinkOut - more resources